Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMVT-1402 · 7 trials · 6 indications
The clinESSDAI is a tool used in clinical studies to measure the systemic disease activity in participants with primary Sjogren's syndrome.
The CLASI-A score represents the overall severity of cutaneous lupus erythematosus (CLE) dermatologic involvement. It is used to assess the activity of mucocutaneous lesions in patients with lupus. The score ranges from 0 (no active lesions) to a maximum of 70. Values between 1 and 9 indicate mild inflammation, 10 to 20 indicate moderate inflammation, and 21 or higher indicate severe inflammation.
| Arm | Type | Description |
|---|---|---|
| Group 1: IMVT-1402 Dose 1 | EXPERIMENTAL | - |
| Group 2: IMVT-1402 Dose 2 | EXPERIMENTAL | - |
| Placebo/ IMVT-1402 | PLACEBO_COMPARATOR | - |
| Group A | EXPERIMENTAL | - |
| Group B | NO_INTERVENTION | - |
| Group C | NO_INTERVENTION | - |
| Placebo | PLACEBO_COMPARATOR | - |
| IMVT-1402 Dose 1 | EXPERIMENTAL | - |
| IMVT-1402 Dose 2 | EXPERIMENTAL | - |
| Period 1: Placebo | PLACEBO_COMPARATOR | Matching placebo for 12 weeks in Period 1 |
| IMVT-1402 Subcutaneous (SC) Once weekly (QW) | EXPERIMENTAL | * Period 1: IMVT-1402 Dose 1 SC QW for 12 weeks * Period 2: IMVT-1402 Dose 1 SC QW for 14 weeks * Period 3: IMVT-1402 Dose 1 or Dose 2 SC QW for 26 weeks |
| Group 1 Period 1 and 2: IMVT-1402 | EXPERIMENTAL | - |
| Group 2 Period 1 and 2: IMVT-1402 | EXPERIMENTAL | - |
| Group 2 Period 1: IMVT-1402 and Period 2: Placebo | EXPERIMENTAL | - |
| Group 3 Period 1 and 2: Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| IMVT-1402 | DRUG | • Dose 1 subcutaneous (SC) once weekly (QW) for 12 weeks (Period 1) |
| Placebo | DRUG | • Placebo SC QW for 12 weeks (Period 1) |
Inclusion Criteria: * Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures. * Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, or IVa at th...
IMVT-1402 is an investigational small molecule being developed for Primary Sjögren's Syndrome, Graves' Disease, Generalized Myasthenia Gravis, Rheumatoid Arthritis, and Subacute Cutaneous Lupus Erythematosus. It is currently in Phase 3 clinical development for these indications.
IMVT-1402 is being developed by Immunovant, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IMVT. The company is conducting clinical trials to evaluate the drug's efficacy and safety in multiple autoimmune conditions.
IMVT-1402 is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Active trials are ongoing for Rheumatoid Arthritis, Primary Sjögren's Syndrome, and Graves' Disease, with additional studies planned.
IMVT-1402 is being studied in several Phase 2 trials, including NCT06754462 for Rheumatoid Arthritis, NCT06979531 for Primary Sjögren's Syndrome, and NCT07018323 for Graves' Disease. A long-term extension study, NCT07286006, is also enrolling patients with Graves' Disease.
IMVT-1402 is a distinct investigational compound developed by Immunovant. No alternative names have been reported for this drug. It is being evaluated as a potential treatment for various autoimmune diseases, but it is not yet approved for any indication.